# US 2024/0124419 A1 · Small molecule inhibitors of grp78 and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0124419 A1
- Document ID: US20240124419A1
- Status: Published application
- Kind: A1
- Application number: 18/273,942
- Filed: 2022-02-02
- Published: 2024-04-18
- Earliest claimed: 2021-02-02
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: Nouri Neamati; Joyeeta Roy; Soma Samanta; Suhui Yang; Ding Xue
- Web page: https://patentgrep.com/patent/US20240124419A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 215/26: Alcohols; Ethers thereof
- C07D 215/28: with halogen atoms or nitro radicals in positions 5, 6 or 7
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/14: containing three or more hetero rings
- C07D 487/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules as defined within Formula I (as defined herein) which function as inhibitors of glucose-regulated protein 78 (GRP78) within cancer cells and/or immune cells, and which function as effective therapeutic agents for treating, ameliorating, and preventing various forms of cancer (e.g., pancreatic cancer), viral infections (e.g. SARS-CoV-2), and inflammatory diseases. In addition, this invention also relates to a new class of PROTACs having Formulas II, III and IV (as defined herein) which function as degraders of GRP78 within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds of Formulas I, II, III, or IV are also within the scope of the present invention.

## Claims

### Claim 1

A compound described by Formula I:
including pharmaceutically acceptable salts (e.g., 2,2,2-trifluoroacetate (TFA) salts and other salts) (e.g., physiologically tolerated acid addition salts), solvates, and/or prodrugs thereof; wherein A, B, E, X1, X2, X3, X4, X5, X6, Y2, Y3, Y4, Y5, Y6 and Z independently include any chemical moiety that permits the resulting compound capable of inhibiting GRP78.

### Claim 2 (depends on 1)

The compound of claim 1, wherein A, B, E, X1, X2, X3, X4, X5, X6, Y2, Y3, Y4, Y5, Y6 and Z independently include any chemical moiety that permits the resulting compound capable of one or more of:
serving as an effective therapeutic agent for treating, ameliorating, and preventing various forms of cancer, viral infections, and inflammatory diseases;
inducing ER stress-mediated apoptosis in the tumor cells implanted in mice without major toxicity to normal tissues; and
inducing ER stress and triggers UPR by inhibiting GRP78.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
X1 is either CH or N;
X2, X3, X4, X5 and X6 are each independently selected from CR1 or N, with the proviso that at least three of them must be CR1;
A is selected from CO, SO, and SO2;
Y2, Y3, Y4, Y5, Y6 are each independently selected from CH, CR2 and N;
Y5 is a bond, in which case one of Y3, Y4, or Y6 is NR2, O, or S, while the other two may be CR2 or N;
B, E are each independently selected from hydrogen and R3;
Z is R3;
R1 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano, CH2F, CHF2, CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, —N(R7)C2-6 alkyl-R4, N(C2-6 alkyl)2-NR7, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than three R1 can be other than H;
R2 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano,
CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, N(C2-6 alkyl)2-NR7, CF3, CO2Et, CO2H, R4, —N(R7)C2-6 alkyl-R4, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than two R2 can be other than H;
R3 is independently selected from the group consisting of C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclic heteroaryl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C0-6 R4, and —N(R7)C2-6 alkyl-R4;
R4 is independently selected from the group consisting of OH, NR5R6, O(CH2)qNR5R6—, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, cyclopropyl, oxetanyl, oxetanyloxy, oxetanylamino, oxolanyl, oxolanyloxy, oxolanylamino, oxanyl oxanyloxy, oxanylamino, oxepanyl, oxepanyloxy, oxepanylamino, azetidinyl, azetidinyloxy, azetidylamino, pyrrolidinyl, pyrolidinyloxy, pyrrolidinylamino, piperidinyl, piperidinyloxy, piperidinylamino, azepanyl, azepanyloxy, azepanylamino, dioxolanyl, dioxanyl, morpholino, thiomorpholino, thiomorpholino-S,S-dioxide, piperazino, dioxepanyl, dioxepanyloxy, dioxepanylamino, oxazepanyl, oxazepanyloxy, oxazepanylamino, diazepanyl, diazepanyloxy, and diazepanylamino, all of which may be optionally substituted with OH, OR7, oxo, halogen, R6, CH2OR6, CH2NR5R6 or CH2CH2CONR5R6;
R5 and R6 are each independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-s cycloalkyl, —(C1-3 alkyl)-(C3-8 cycloalkyl), C3-8 cycloalkenyl, C1-C6 acyl, 4-12 membered monocyclic or bicyclic heterocyclyl, 4-12 membered monocyclic or bicyclic heterocyclyl-C1-C6 alkyl-, C6-C12 aryl, and 5-11 membered heteroaryl; wherein R5 and R6 may be further independently substituted with up to three substituents selected from the group consisting of hydroxyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, oxo, thiono, cyano, and halo; or alternatively, R5 and R6, taken together with the N atom to which they are both attached, may form a heterocycloalkyl ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3, or a heterobicycloalkyl ring of 6-12 members which may be fused, bridged or spiro, and contain up to two other heteroatoms chosen from O, S(O)x, or NR3;
each R7 is independently selected from H, —CD3, C1-6 alkyl, C3-6 cycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, C2-6 hydroxyalkyl, —SO2-alkyl, NH-C2-6 alkyl-NR5R6, C1-6 alkoxy-C1-6 alkyl, and C2-6 alkyl-NR5R6; alternatively, two R7 taken together with the same N atom to which they are both attached, form a heterocyclic ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3;
p=0, 1, 2, 3, or 4;
x=0, 1, or 2.

### Claim 4

A compound described by Formula I:
including pharmaceutically acceptable salts (e.g., 2,2,2-trifluoroacetate (TFA) salts and other salts) (e.g., physiologically tolerated acid addition salts), solvates, and/or prodrugs thereof; wherein A, B, E, X1, X2, X3, X4, X5, X6, Y2, Y3, Y4, Y5, Y6 and Z independently include any chemical moiety that permits the resulting compound capable of inhibiting GRP78.

### Claim 5 (depends on 4)

The compound of claim 4, wherein A, B, X1, X2, X3, X4, X5, X6, and Z independently include any chemical moiety that permits the resulting compound capable of one or more of:
serving as an effective therapeutic agent for treating, ameliorating, and preventing various forms of cancer, viral infections, and inflammatory diseases;
inducing ER stress-mediated apoptosis in the tumor cells implanted in mice without major toxicity to normal tissues; and
inducing ER stress and triggers UPR by inhibiting GRP78.

### Claim 6 (depends on 4)

The compound of claim 4, wherein:
X1 is either CH or N;
X2, X3, X4, X5 and X6 are independently selected from CR1 or N, with the proviso that at least three of them must be CR1;
A is selected from CO, SO, and SO2;
B and Z are each independently selected from hydrogen and R3;
R1 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano, CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, —N(R7)C2-6 alkyl-R4, N(C2-6 alkyl)2-NR7, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than three R1 can be other than H;
R4 is independently selected from the group consisting of OH, NR5R6, O(CH2)qNR5R6, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, cyclopropyl, oxetanyl, oxetanyloxy, oxetanylamino, oxolanyl, oxolanyloxy, oxolanylamino, oxanyl oxanyloxy, oxanylamino, oxepanyl, oxepanyloxy, oxepanylamino, azetidinyl, azetidinyloxy, azetidylamino, pyrrolidinyl, pyrolidinyloxy, pyrrolidinylamino, piperidinyl, piperidinyloxy, piperidinylamino, azepanyl, azepanyloxy, azepanylamino, dioxolanyl, dioxanyl, morpholino, thiomorpholino, thiomorpholino-S,S-dioxide, piperazino, dioxepanyl, dioxepanyloxy, dioxepanylamino, oxazepanyl, oxazepanyloxy, oxazepanylamino, diazepanyl, diazepanyloxy, and diazepanylamino, all of which may be optionally substituted with OH, OR7, oxo, halogen, R6, CH2OR6, CH2NR5R6 or CH2CH2CONR5R6;
R5 and R6 are each independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-s cycloalkyl, —(C1-3 alkyl)-(C3-s cycloalkyl), C3-8 cycloalkenyl, C1-C6 acyl, 4-12 membered monocyclic or bicyclic heterocyclyl, 4-12 membered monocyclic or bicyclic heterocyclyl-C1-C6 alkyl-, C6-C12 aryl, and 5-11 membered heteroaryl; wherein R5 and R6 may be further independently substituted with up to three substituents chosen from hydroxyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, oxo, thiono, cyano or halo; or alternatively, R5 and R6, taken together with the N atom to which they are both attached, form a heterocycloalkyl ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3, or a heterobicycloalkyl ring of 6-12 members which may be fused, bridged or spiro, and contain up to two other heteroatoms chosen from O, S(O)x, or NR3;
each R7 is independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 cycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, C2-6 hydroxyalkyl, —SO2-alkyl, NH—C2-6 alkyl-NR5R6, C1-6 alkoxy-C1-6 alkyl, and C2-6 alkyl-NR5R6;
alternatively, two R7 taken together with the same N atom to which they are both attached, form a heterocyclic ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3;
p=0, 1, 2, 3, or 4;
x=0, 1, or 2.

### Claim 7

A compound described by Formula Ib:
including pharmaceutically acceptable salts (e.g., 2,2,2-trifluoroacetate (TFA) salts and other salts) (e.g., physiologically tolerated acid addition salts), solvates, and/or prodrugs thereof; wherein A, B, X1, X2, X3, X4, X5, X6 and Z independently include any chemical moiety that permits the resulting compound capable of inhibiting GRP78.

### Claim 8 (depends on 7)

The compound of claim 7, wherein A, B, X1, X2, X3, X4, X5, X6, and Z independently include any chemical moiety that permits the resulting compound capable of one or more of:
serving as an effective therapeutic agent for treating, ameliorating, and preventing various forms of cancer, viral infections, and inflammatory diseases;
inducing ER stress-mediated apoptosis in the tumor cells implanted in mice without major toxicity to normal tissues; and
inducing ER stress and triggers UPR by inhibiting GRP78.

### Claim 9 (depends on 7)

The compound of claim 7, wherein:
X1 is either CH or N;
X2, X3, X4, X5 and X6 are independently selected from CR1 or N, with the proviso that at least three of them must be CR1;
A is selected from the group consisting of CO, SO, and SO2;
B, Z are each independently hydrogen or R3;
R1 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano, CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, —N(R7)C2-6 alkyl-R4, N(C2-6 alkyl)2-NR7, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than three R1 can be other than H;
R4 is independently selected from the group consisting of OH, NR5R6, O(CH2)qNR5R6, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, cyclopropyl, oxetanyl, oxetanyloxy, oxetanylamino, oxolanyl, oxolanyloxy, oxolanylamino, oxanyl oxanyloxy, oxanylamino, oxepanyl, oxepanyloxy, oxepanylamino, azetidinyl, azetidinyloxy, azetidylamino, pyrrolidinyl, pyrolidinyloxy, pyrrolidinylamino, piperidinyl, piperidinyloxy, piperidinylamino, azepanyl, azepanyloxy, azepanylamino, dioxolanyl, dioxanyl, morpholino, thiomorpholino, thiomorpholino-S,S-dioxide, piperazino, dioxepanyl, dioxepanyloxy, dioxepanylamino, oxazepanyl, oxazepanyloxy, oxazepanylamino, diazepanyl, diazepanyloxy, and diazepanylamino, all of which may be optionally substituted with OH, OR7, oxo, halogen, R6, CH2OR6, CH2NR5R6 or CH2CH2CONR5R6;
wherein R5 and R6 are each independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-s cycloalkyl, —(C1-3 alkyl)-(C3-8 cycloalkyl), C3-8 cycloalkenyl, C1-C6 acyl, 4-12 membered monocyclic or bicyclic heterocyclyl, 4-12 membered monocyclic or bicyclic heterocyclyl-C1-C6 alkyl-, C6-C12 aryl, and 5-11 membered heteroaryl; wherein R5 and R6 may be further independently substituted with up to three substituents chosen from hydroxyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, oxo, thiono, cyano or halo; or alternatively, R5 and R6, taken together with the N atom to which they are both attached, form a heterocycloalkyl ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3, or a heterobicycloalkyl ring of 6-12 members which may be fused, bridged or spiro, and contain up to two other heteroatoms chosen from O, S(O)x, or NR3;
R7 is independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 cycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, C2-6 hydroxyalkyl, —SO2-alkyl, NH—C2-6 alkyl-NR5R6, C1-6 alkoxy-C1-6 alkyl, and C2-6 alkyl-NR5R6; alternatively, two R7 taken together with the same N atom to which they are both attached, form a heterocyclic ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3;
p=0, 1, 2, 3, or 4;
x=0, 1, or 2.

### Claim 10

A compound described by Formula II:
including pharmaceutically acceptable salts (e.g., 2,2,2-trifluoroacetate (TFA) salts and other salts) (e.g., physiologically tolerated acid addition salts), solvates, and/or prodrugs thereof; wherein X1, X2, X3, X4, X5, X6, Y2, Y3, Y4, Y5, Y6, A, B, E, L and Z independently include any chemical moiety that permits the resulting compound capable of inhibiting and/or degrading GRP78.

### Claim 11 (depends on 10)

The compound of claim 10, wherein X1, X2, X3, X4, X5, X6, Y2, Y3, Y4, Y5, Y6, A, B, E, L and Z independently include any chemical moiety that permits the resulting compound capable of one or more of:
serving as an effective therapeutic agent for treating, ameliorating, and preventing various forms of cancer, viral infections, and inflammatory diseases;
inducing ER stress-mediated apoptosis in the tumor cells implanted in mice without major toxicity to normal tissues; and
inducing ER stress and triggers UPR by inhibiting GRP78.

### Claim 12 (depends on 10)

The compound of claim 10, wherein:
X1 is either CH or N;
X2, X3, X4, X5 and X6 are each independently selected from CR1 and N, with the proviso that at least three of them must be CR1;
A is selected from the group consisting of CO, SO, and SO2;
Y2, Y3, Y4, Y5, Y6 are each independently selected from the group consisting of CH, CR2 and N;
Y5 is a bond, in which case one of Y3, Y4, or Y6 is NR2, O, or S, while the other two may be CR2 or N;
B, E are each independently selected from H and R3;
R1 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano, CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, —N(R7)C2-6 alkyl-R4, N(C2-6 alkyl)2-NR7, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than three R1 can be other than H;
R2 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano,
CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, N(C2-6 alkyl)2-NR7, CF3, CO2Et, CO2H, —N(R7)C2-6 alkyl-R4, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than two R2 can be other than H;
R3 is independently selected from the group consisting of C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclic heteroaryl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, and C1-6 R4;
R4 is independently selected from the group consisting of OH, NR5R6, O(CH2)qNR5R6, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, cyclopropyl, oxetanyl, oxetanyloxy, oxetanylamino, oxolanyl, oxolanyloxy, oxolanylamino, oxanyl oxanyloxy, oxanylamino, oxepanyl, oxepanyloxy, oxepanylamino, azetidinyl, azetidinyloxy, azetidylamino, pyrrolidinyl, pyrolidinyloxy, pyrrolidinylamino, piperidinyl, piperidinyloxy, piperidinylamino, azepanyl, azepanyloxy, azepanylamino, dioxolanyl, dioxanyl, morpholino, thiomorpholino, thiomorpholino-S,S-dioxide, piperazino, dioxepanyl, dioxepanyloxy, dioxepanylamino, oxazepanyl, oxazepanyloxy, oxazepanylamino, diazepanyl, diazepanyloxy, and diazepanylamino, all of which may be optionally substituted with OH, OR7, oxo, halogen, R6, CH2OR6, CH2NR5R6 or CH2CH2CONR5R6;
R5 and R6 are each independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-s cycloalkyl, —(C1-3 alkyl)-(C3-s cycloalkyl), C3-s cycloalkenyl, C1-C6 acyl, 4-12 membered monocyclic or bicyclic heterocyclyl, 4-12 membered monocyclic or bicyclic heterocyclyl-C1-C6 alkyl-, C6-C12 aryl, and 5-11 membered heteroaryl; wherein R5 and R6 may be further independently substituted with up to three substituents chosen from hydroxyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, oxo, thiono, cyano or halo; or alternatively, R5 and R6, taken together with the N atom to which they are both attached, form a heterocycloalkyl ring of 4-7 members, containing up to one other heteroatom selected from 0, S, or NR3, or a heterobicycloalkyl ring of 6-12 members which may be fused, bridged or spiro, and contain up to two other heteroatoms chosen from O, S(O)x, or NR3;
R7 is independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 cycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, C2-6 hydroxyalkyl, —SO2-alkyl, NH—C2-6 alkyl-NR5R6, C1-6 alkoxy-C1-6 alkyl, and C2-6 alkyl-NR5R6; alternatively, two R7 taken together with the same N atom to which they are both attached, form a heterocyclic ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3;
p=0, 1, 2, 3, or 4;
x=0, 1, or 2;
L is a linker selected from a group consisting of —(CH2)m-, —(CH2CH2O)n-,
—(CH2CH2O)nC≡C;
m=0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
n=0, 1, 2, 3, 4, 5, or 6;
Z is a radical of an E3 ligase ligand selected from the group consisting of:

### Claim 13

A compound described by Formula III:
including pharmaceutically acceptable salts (e.g., 2,2,2-trifluoroacetate (TFA) salts and other salts) (e.g., physiologically tolerated acid addition salts), solvates, and/or prodrugs thereof; wherein X1, X2, X3, X4, X5, X6, Y2, Y3, Y4, Y5, A, B, E, J, L and Z independently include any chemical moiety that permits the resulting compound capable of inhibiting GRP78.

### Claim 14 (depends on 13)

The compound of claim 13, wherein X1, X2, X3, X4, X5, X6, Y2, Y3, Y4, Y5, A, B, E, J, L and Z independently include any chemical moiety that permits the resulting compound capable of one or more of:
serving as an effective therapeutic agent for treating, ameliorating, and preventing various forms of cancer, viral infections, and inflammatory diseases;
inducing ER stress-mediated apoptosis in the tumor cells implanted in mice without major toxicity to normal tissues; and
inducing ER stress and triggers UPR by inhibiting GRP78.

### Claim 15 (depends on 13)

The compound of claim 13, wherein:
X1 is either CH or N;
X2, X3, X4, X5 and X6 are each independently selected from CR1 and N, with the proviso that at least three of them must be CR1;
A is selected from CO, SO, and SO2;
Y2, Y3, Y4, Y5 are independently selected from CH, CR2 and N;
B, E and J are each independently selected from H and R3;
R1 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano, CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, —N(R7)C2-6 alkyl-R4, N(C2-6 alkyl)2-NR7, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than three R1 can be other than H;
R2 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano, CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, N(C2-6 alkyl)2-NR7, CF3, CO2Et, CO2H, —N(R7)C2-6 alkyl-R4, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than two R2 can be other than H;
R3 is independently selected from the group consisting of C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclic heteroaryl, C1-6 alkyl-C3-7 cycloalkyl, or C1-6 alkyl-C4-7 heterocycloalkyl, and C1-6 R4;
R4 is independently selected from the group consisting of OH, NR5R6, O(CH2)qNR5R6, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, cyclopropyl, oxetanyl, oxetanyloxy, oxetanylamino, oxolanyl, oxolanyloxy, oxolanylamino, oxanyl oxanyloxy, oxanylamino, oxepanyl, oxepanyloxy, oxepanylamino, azetidinyl, azetidinyloxy, azetidylamino, pyrrolidinyl, pyrolidinyloxy, pyrrolidinylamino, piperidinyl, piperidinyloxy, piperidinylamino, azepanyl, azepanyloxy, azepanylamino, dioxolanyl, dioxanyl, morpholino, thiomorpholino, thiomorpholino-S,S-dioxide, piperazino, dioxepanyl, dioxepanyloxy, dioxepanylamino, oxazepanyl, oxazepanyloxy, oxazepanylamino, diazepanyl, diazepanyloxy, and diazepanylamino, all of which may be optionally substituted with OH, OR7, oxo, halogen, R6, CH2OR6, CH2NR5R6 or CH2CH2CONR5R6;
R5 and R6 are each independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-s cycloalkyl, —(C1-3 alkyl)-(C3-s cycloalkyl), C3-s cycloalkenyl, C1-C6 acyl, 4-12 membered monocyclic or bicyclic heterocyclyl, 4-12 membered monocyclic or bicyclic heterocyclyl-C1-C6 alkyl-, C6-C12 aryl, and 5-11 membered heteroaryl; wherein R5 and R6 may be further independently substituted with up to three substituents chosen from hydroxyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, oxo, thiono, cyano or halo; or alternatively, R5 and R6, taken together with the N atom to which they are both attached, form a heterocycloalkyl ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3, or a heterobicycloalkyl ring of 6-12 members which may be fused, bridged or spiro, and contain up to two other heteroatoms chosen from O, S(O)x, or NR3;
R7 is independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 cycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, C2-6 hydroxyalkyl, —SO2-alkyl, NH—C2-6 alkyl-NR5R6, C1-6 alkoxy-C1-6 alkyl, and C2-6 alkyl-NR5R6;
alternatively, two R7 taken together with the same N atom to which they are both attached, form a heterocyclic ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3;
p=0, 1, 2, 3, or 4;
x=0, 1, or 2;
L is a linker selected from a group consisting of —(CH2)m—, —NH(CH2)m—, —NH(CH2CH2O)n—, —(CH2CH2O)n—, —(CH2)mCO—, —(CH2CH2O)nCO—,
—NH(CH2)mC≡C, and —NH(CH2CH2O)nC≡C;
m=0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
n=0, 1, 2, 3, 4, 5, or 6;
Z is a radical of an E3 ligase ligand selected from the group consisting of:

### Claim 16

A compound described by Formula IV:
including pharmaceutically acceptable salts (e.g., 2,2,2-trifluoroacetate (TFA) salts and other salts) (e.g., physiologically tolerated acid addition salts), solvates, and/or prodrugs thereof;
wherein X1, X2, X3, X4, X5, Y2, Y3, Y4, Y5, Y6, A, B, E, M, J, L and Z independently include any chemical moiety that permits the resulting compound capable of inhibiting GRP78.

### Claim 17 (depends on 16)

The compound of claim 16, wherein X1, X2, X3, X4, X5, Y2, Y3, Y4, Y5, Y6, A, B, E, M, J, L and Z independently include any chemical moiety that permits the resulting compound capable of one or more of:
serving as an effective therapeutic agent for treating, ameliorating, and preventing various forms of cancer, viral infections, and inflammatory diseases;
inducing ER stress-mediated apoptosis in the tumor cells implanted in mice without major toxicity to normal tissues; and
inducing ER stress and triggers UPR by inhibiting GRP78.

### Claim 18 (depends on 16)

The compound of claim 16, wherein:
X1 is either CH or N;
X2, X3, X4, X5 are independently selected from CR1 and N, with the proviso that at least three of them must be CR1;
A is selected from the group consisting of CO, SO, and SO2;
Y2, Y3, Y4, Y5 are independently selected from the group consisting of CH, CR2 or N;
M is selected from the group consisting of NH and CO;
B, E and J are each independently selected from the group consisting of H and R3;
R1 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano, CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, —N(R7)C2-6 alkyl-R4, N(C2-6 alkyl)2-NR7, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than three R1 can be other than H;
R2 is independently selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, C1-6 alkyl-phenyl, C1-6 alkyl-naphthyl, C1-6 alkyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkenyl-C3-7 cycloalkyl, C2-6 alkenyl-C4-7 heterocycloalkyl, C2-6 alkenyl-phenyl, C2-6 alkenyl-naphthyl, C2-6 alkenyl-(5-10 membered mono- or bicyclo-heteroaryl), C2-6 alkynyl-C3-7 cycloalkyl, C2-6 alkynyl-C4-7 heterocycloalkyl, C2-6 alkynyl-phenyl, C2-6 alkynyl-naphthyl, C2-6 alkynyl-(5-10 membered mono- or bicyclo-heteroaryl), phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, hydroxyl, C1-6 alkoxy, C1-6 alkoxy-C3-7 cycloalkyl, C1-6 alkoxy-C4-7 heterocycloalkyl, C1-6 alkoxy-phenyl, C1-6 alkoxy-naphthyl, C1-6 alkoxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 acyloxy, C1-6 acyloxy, C1-6 acyloxy-C3-7 cycloalkyl, C1-6 acyloxy-C4-7 heterocycloalkyl, C1-6 acyloxy-phenyl, C1-6 acyloxy-naphthyl, C1-6 acyloxy-(5-10 membered mono- or bicyclo-heteroaryl), C1-6 thioalkoxy, C1-6 thioalkoxy, C1-6 thioalkoxy-C3-7 cycloalkyl, C1-6 thioalkoxy-C4-7 heterocycloalkyl, C1-6 thioalkoxy-phenyl, C1-6 thioalkoxy-naphthyl, C1-6 thioalkoxy-(5-10 membered mono- or bicyclo-heteroaryl), amino, C1-6 monoalkylamino, C1-6 dialkylamino, C1-6 acyl, C1-6 acylamino, cyano,
CF3, OCF3, SOR7, SO2R7, NO2, COR4, C1-6 alkyl-COR4, N(R7)C2-6 alkyl-NR7R7, N(C2-6 alkyl)2-NR7, CF3, CO2Et, CO2H, —N(R7)C2-6 alkyl-R4, —O(CH2)pR4, —S(CH2)pR4, and —N(R7)C(═O)(CH2)pR4, with a proviso that not more than two R2 can be other than H;
R3 is independently selected from the group consisting of C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl, C4-7 heterocycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclic heteroaryl, C1-6 alkyl-C3-7 cycloalkyl, C1-6 alkyl-C4-7 heterocycloalkyl, and C1-6 R4;
R4 is independently selected from the group consisting of OH, NR5R6, O(CH2)qNR5R6, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, cyclopropyl, oxetanyl, oxetanyloxy, oxetanylamino, oxolanyl, oxolanyloxy, oxolanylamino, oxanyl oxanyloxy, oxanylamino, oxepanyl, oxepanyloxy, oxepanylamino, azetidinyl, azetidinyloxy, azetidylamino, pyrrolidinyl, pyrolidinyloxy, pyrrolidinylamino, piperidinyl, piperidinyloxy, piperidinylamino, azepanyl, azepanyloxy, azepanylamino, dioxolanyl, dioxanyl, morpholino, thiomorpholino, thiomorpholino-S,S-dioxide, piperazino, dioxepanyl, dioxepanyloxy, dioxepanylamino, oxazepanyl, oxazepanyloxy, oxazepanylamino, diazepanyl, diazepanyloxy, and diazepanylamino, all of which may be optionally substituted with OH, OR7, oxo, halogen, R6, CH2OR6, CH2NR5R6 or CH2CH2CONR5R6;
R5 and R6 are each independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-s cycloalkyl, —(C1-3 alkyl)-(C3-s cycloalkyl), C3-8 cycloalkenyl, C1-C6 acyl, 4-12 membered monocyclic or bicyclic heterocyclyl, 4-12 membered monocyclic or bicyclic heterocyclyl-C1-C6 alkyl-, C6-C12 aryl, and 5-11 membered heteroaryl; wherein R5 and R6 may be further independently substituted with up to three substituents chosen from hydroxyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 alkoxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkoxy, C2-6 hydroxyalkoxy, oxo, thiono, cyano or halo; or alternatively, R5 and R6, taken together with the N atom to which they are both attached, form a heterocycloalkyl ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3, or a heterobicycloalkyl ring of 6-12 members which may be fused, bridged or spiro, and contain up to two other heteroatoms chosen from O, S(O)x, or NR3;
R7 is independently selected from the group consisting of H, —CD3, C1-6 alkyl, C3-6 cycloalkyl, phenyl, naphthyl, 5-10 membered mono- or bicyclo-heteroaryl, C2-6 hydroxyalkyl, —SO2-alkyl, NH—C2-6 alkyl-NR5R6, C1-6 alkoxy-C1-6 alkyl, and C2-6 alkyl-NR5R6; alternatively, two R7 taken together with the same N atom to which they are both attached, form a heterocyclic ring of 4-7 members, containing up to one other heteroatom selected from O, S, or NR3;
p=0, 1, 2, 3, or 4;
x=0, 1, or 2;
L is a linker selected from a group consisting of —CO(CH2)m—, —NH(CH2)m—, —NH(CH2CH2O)n—, —CO(CH2CH2O)n—, —NH(CH2)mCO—, —NH(CH2CH2O)nCO—,
—NH(CH2)mC≡C, —NH(CH2CH2O)nC≡C—CO(CH2)mC≡C, and —CO(CH2CH2O)nC≡C;
m=0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
n=0, 1, 2, 3, 4, 5, or 6;
Z is a radical of an E3 ligase ligand selected from the group consisting of:

### Claim 19

A compound selected from one of the compounds recited in Tables I or II.

### Claim 20 (depends on 1, 4, 7, 10, 13, 16, 19)

A pharmaceutical composition comprising a compound recited claim 1, 4, 7, 10, 13, 16 or 19.

### Claim 21 (depends on 20)

A method of treating, ameliorating, or preventing a disorder related to GRP78 activity in a patient comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 20.

### Claim 22 (depends on 21)

The method of claim 21, wherein said disorder related to GRP78 activity is a hyperproliferative condition and/or inflammatory condition.

### Claim 23 (depends on 22)

The method of claim 22, wherein the inflammatory condition is a chronic auto immune disorder and/or a viral infection such as SARS CoV-2.

### Claim 24 (depends on 22)

The method of claim 22, wherein the hyperproliferative condition is diabetes and/or cancer.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cancer is one or more of pancreatic cancer, leukemia, colon cancer, CNS cancers (e.g. glioblastoma), non-small lung cancer, melanoma, ovarian cancer, renal cancer, breast cancer, prostate cancer, esophageal cancer, cervical cancer and colorectal cancer.

### Claim 26 (depends on 21)

The method of claim 21, wherein said patient is a human patient.

### Claim 27 (depends on 21)

The method of claim 21, further comprising administering to said patient one or more agents for treating the disorder related to GRP78 activity.

### Claim 28 (depends on 27)

The method of claim 27, wherein the agents comprise topoisomerase I inhibitors and HDAC inhibitors.

### Claim 29 (depends on 27)

The method of claim 27, wherein the agents comprise anticancer agents, wherein said anticancer agent one or more of a chemotherapeutic agent, and radiation therapy.

### Claim 30 (depends on 21)

The method of claim 21, wherein administration of the compound results in induced ER stress-mediated apoptosis in the tumor cells implanted in mice without major toxicity to normal tissues.

### Claim 31 (depends on 21)

The method of claim 21, wherein administration of the compound induces ER stress and triggers UPR by inhibiting GRP78.
